Prediction of the pharmacokinetics and pharmacodynamics of topiroxostat in humans by integrating the physiologically based pharmacokinetic model with the drug-target residence time model

Prediction of the pharmacokinetics and pharmacodynamics of topiroxostat in humans by integrating the physiologically based pharmacokinetic model with the drug-target residence time model

Topiroxostat is a selective xanthine oxidoreductase (XOR) inhibitor for the management of hyperuricemia in patients with or without gout. In this work, we aim to employ the physiologically based pharmacokinetic (PBPK) model with the drug-target residence time model to predict and characterize both t...

Full description

Bibliographic Details
Main Authors: Zhiqiang Luo, Guohua Yu, Xing Han, Tingting Yang, Yanhua Ji, Huating Huang, Guopeng Wang, Yang Liu, Wenyan Sun
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Topiroxostat
PBPK model
Residence time
GastroPlus
Target occupancy
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332219352825

Internet

http://www.sciencedirect.com/science/article/pii/S0753332219352825

Similar Items